"studyid","tsseq","actsub","adapt","addon","agemax","agemin","agespan","dcutdesc","dcutdtc","dose","dosfrq","dosu","fcntry","hltsubji","indic","intmodel","inttype","length","narms","objprim","objsec","outmspri","pclas","plansub","random","regid","route","sendtc","sexpop","sponsor","sstdtc","stoprule","stype","tblind","tcntrl","tdigrp","tindtp","title","tphase","trt","ttype","tblind_im"
"CDISCPILOT01",1,"254","N","N","","P50Y","ADULT (18-65)","Interim Analysis Data Cutoff Date","2015-03-31","54","QD","mg","USA","N","Alzheimer's Disease (Disorder)","PARALLEL","DRUG","P26W","3","To determine if there is a statistically significant relationship between the change in both ADAS-Cog and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg])","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas.","Evaluate the efficacy and safety of transdermal xanomeline, 50cm2 and 75cm2, and placebo in subjects with mild to moderate Alzheimer's disease.","Acetylcholine Release Inhibitor","300","Y","NCT00987090","TRANSDERMAL","2015-03-05","BOTH","CDISCPILOT01","2012-07-06","Last patient completed last visit or sponsor decided to discontinue study","INTERVENTIONAL","DOUBLE BLIND","PLACEBO","Patients with Probable Mild to Moderate Alzheimer’s Disease","TREATMENT","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease.","PHASE II TRIAL","Xanomeline","SAFETY","DOUBLE_BLIND"
"CDISCPILOT01",2,,,,,,"ELDERLY (> 65)",,,"81",,,,,,,,,,"To document the safety profile of the xanomeline TTS.","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas.",,,,,,,,,,,,,,,,,,,,"EFFICACY",
"CDISCPILOT01",3,,,,,,,,,,,,,,,,,,,,"To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The ADAS-Cog (14) will be used for this assessment.",,,,,,,,,,,,,,,,,,,,,
"CDISCPILOT01",4,,,,,,,,,,,,,,,,,,,,"To assess the treatment response as a function of Apo E genotype.",,,,,,,,,,,,,,,,,,,,"PHARMACOKINETIC",
